These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20504363)

  • 1. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
    Sharon E; Kelly RJ; Szabo E
    Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
    Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
    Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab for the treatment of salivary duct carcinoma.
    Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
    Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.
    Mihaljevic A; Büchler P; Harder J; Hofheinz R; Gregor M; Kanzler S; Schmiegel W; Heinemann V; Endlicher E; Klöppel G; Seufferlein T; Geissler M
    BMC Surg; 2009 Jan; 9():1. PubMed ID: 19133157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
    Lázaro A; Casinello J; Amorós A; Heredia M; López-Alfonso A
    Clin Transl Oncol; 2008 Sep; 10(9):587-90. PubMed ID: 18796377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma.
    Arihara Y; Murase K; Takada K; Hayasaka N; Miura S; Miyanishi K; Kobune M; Kurose M; Akiyama Y; Sugita S; Kato J
    Case Rep Oncol; 2018; 11(3):835-841. PubMed ID: 30687059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
    Bouché O; Penault-Llorca F
    Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
    Sbitti Y; Essaidi I; Debbagh A; Kadiri H; Oukabli M; Moussaid Y; Slimani K; Fetohi M; Elkaoui H; Albouzidi A; Mahi M; Ali AA; Ichou M; Errihani H
    World J Surg Oncol; 2011 Sep; 9():112. PubMed ID: 21955806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
    Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
    Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
    Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
    von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
    Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
    Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
    Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
    Wildiers H; Neven P; Christiaens MR; Squifflet P; Amant F; Weltens C; Smeets A; van Limbergen E; Debrock G; Renard V; Van Eenoo L; Wynendaele W; Paridaens R
    Ann Oncol; 2011 Mar; 22(3):588-594. PubMed ID: 20709813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
    Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
    Osako T; Ito Y; Takahashi S; Tokudome N; Iwase T; Hatake K
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):159-64. PubMed ID: 17882419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.